CytoMed Therapeutics (GDTC) Shares Outstanding (Diluted Average) (2021 - 2025)
CytoMed Therapeutics (GDTC) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $9.0 million as the latest value for Q4 2025.
- Quarterly Shares Outstanding (Diluted Average) rose 3.59% to $9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, up 3.59% year-over-year, with the annual reading at $8.9 million for FY2025, 3.19% up from the prior year.
- Shares Outstanding (Diluted Average) hit $9.0 million in Q4 2025 for CytoMed Therapeutics, up from $8.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $9.0 million in Q4 2025 to a low of $5.1 million in Q4 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $7.3 million across 5 years, with a median of $7.9 million in 2023.
- Biggest five-year swings in Shares Outstanding (Diluted Average): soared 38.06% in 2023 and later rose 3.59% in 2025.
- Year by year, Shares Outstanding (Diluted Average) stood at $5.1 million in 2021, then rose by 11.61% to $5.7 million in 2022, then skyrocketed by 38.06% to $7.9 million in 2023, then increased by 10.18% to $8.7 million in 2024, then rose by 3.59% to $9.0 million in 2025.
- Business Quant data shows Shares Outstanding (Diluted Average) for GDTC at $9.0 million in Q4 2025, $8.7 million in Q4 2024, and $7.9 million in Q4 2023.